Regional differences in early stage bladder cancer care and outcomes.
Ted A Skolarus, Zaojun Ye, Sean Zhang...
https://pubmed.ncbi.nlm.nih.gov/20394976/Actively Recruiting
Led by University of Roma La Sapienza · Updated on 2025-12-31
327
Participants Needed
1
Research Sites
156 weeks
Total Duration
Researchers are evaluating a new approach for treating non-muscle-invasive bladder cancers NMIBCs, focusing on avoiding unnecessary second surgeries called repeat transurethral resections of bladder tumors Re-TURBT. This phase IV, open-label, randomized controlled trial compares a modern imaging-guided surgery using photodynamic diagnosis PDD-TURBT after MRI staging with the current standard of care involving white light cystoscopy and mandatory Re-TURBT. The study aims to reduce overtreatment, improve patient quality of life, and lower healthcare costs while ensuring cancer control. Participants will be randomized into two groups one receiving PDD-TURBT without a second surgery, and the other following standard care with white light TURBT followed by Re-TURBT within 2 to 6 weeks. The PDD-TURBT uses a photosensitizer drug hexaminolevulinate inserted into the bladder and special blue light equipment to better detect tumors during surgery. The trial includes a total of 112 participants per arm, with all receiving initial MRI-based VI-RADS scoring to exclude muscle-invasive disease. Throughout the study, participants will undergo regular follow-ups including cystoscopy and imaging to monitor for early bladder cancer recurrence within 4.5 months and later outcomes over three years. Researchers will assess recurrence rates, progression to muscle-invasive cancer, patients health-related quality of life, and cost effectiveness. The study is designed to provide evidence for potentially updating treatment guidelines and reducing the burden of repeated surgeries for bladder cancer patients.
CONDITIONS
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
F
Francesco Del Giudice, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Roma La Sapienza
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 weeks
Participants undergo either primary photodynamic trans-urethral resection of bladder tumor (PDD-TURBT) without repeat surgery or standard white-light TURBT followed by repeat TURBT within 2 to 6 weeks.
1 to 2 surgical visits depending on assigned treatment arm
Duration - Approximately 4.5 months
Participants are monitored with cystoscopy and assessments for bladder cancer recurrence and quality of life over 4.5 months after primary intervention.
1 follow-up visit at 3 months after treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ted A Skolarus, Zaojun Ye, Sean Zhang...
https://pubmed.ncbi.nlm.nih.gov/20394976/Jose Leal, Ramon Luengo-Fernandez, Richard Sullivan...
https://pubmed.ncbi.nlm.nih.gov/26508308/Marko Babjuk, Maximilian Burger, Otakar Capoun...
https://pubmed.ncbi.nlm.nih.gov/34511303/J I Epstein, M B Amin, V R Reuter...
https://pubmed.ncbi.nlm.nih.gov/9850170/Angelo Naselli, Rodolfo Hurle, Stefano Paparella...
https://pubmed.ncbi.nlm.nih.gov/28753839/Jorg Oddens, Maurizio Brausi, Richard Sylvester...
https://pubmed.ncbi.nlm.nih.gov/23141049/Seth A Strope, Zaojun Ye, John M Hollingsworth...
https://pubmed.ncbi.nlm.nih.gov/20310051/Maurizio Brausi, Laurence Collette, Karlheinz Kurth...
https://pubmed.ncbi.nlm.nih.gov/12074794/Tetsuya Shindo, Naoya Masumori, Hiroshi Kitamura...
https://pubmed.ncbi.nlm.nih.gov/24190368/Francesco Del Giudice, Annarita Vestri, Danilo Alunni Fegatelli...
https://pubmed.ncbi.nlm.nih.gov/39397266/University of Roma La Sapienza
Lead Sponsor